Dinan, Timothy G, Stanton, Catherine, Cryan, John F · Biological psychiatry · 2013 · DOI
This review examines 'psychobiotics'—beneficial bacteria that may help with mood and mental health by producing brain chemicals like serotonin. These bacteria communicate with the brain through the gut-brain connection. Early research in animals and some patient studies suggests they might reduce depression, anxiety, and fatigue symptoms, possibly by lowering inflammation and stress hormone levels.
For ME/CFS patients, this review is significant because it highlights a potential mechanism linking gut microbiota composition to fatigue and neuropsychiatric symptoms via inflammation and HPA axis dysfunction—both recognized features of the illness. Understanding psychobiotics could eventually offer a complementary therapeutic approach if larger clinical trials demonstrate efficacy in ME/CFS populations specifically.
This review does not prove that psychobiotics are effective treatments for ME/CFS; it only identifies emerging evidence and proposed mechanisms. The authors explicitly note that large-scale placebo-controlled trials are still awaited, meaning clinical efficacy remains unproven. This is a conceptual review rather than a primary study, so it cannot establish causation or provide robust outcome data.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →